Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kaitlin Baron

Cardiovascular Disease Silver Spring, MD Medical Doctor

NPI 1942576921 CMS profile 1394054

2900 Linden Ln Ste 200, Silver Spring, MD 20910

Open in the dashboard

General payments

$3,760

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaitlin Baron of Silver Spring, MD is reported in the CMS Open Payments database as having received $3,760 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $650 32
2024 General $667 33
2023 General $655 33
2022 General $435 21
2021 General $568 29
2020 General $287 15
2019 General $498 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaitlin Baron
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Kaitlin Baron were reported at $650. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Kaitlin Baron Cardiovascular Disease median Middle half National median
2019 $498 $450 $127–$1,392 $163
2020 $287 $242 $77–$751 $114
2021 $568 $335 $101–$1,037 $132
2022 $435 $395 $121–$1,211 $149
2023 $655 $443 $136–$1,283 $160
2024 $667 $450 $136–$1,323 $164
2025 $650 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $707 37 payments
  2. Novartis Pharmaceuticals Corporation $530 25 payments
  3. Merck Sharp & Dohme Corporation $279 14 payments
  4. Pfizer Inc. $261 15 payments
  5. Janssen Pharmaceuticals, Inc $259 12 payments
  6. AstraZeneca Pharmaceuticals LP $171 11 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $169 7 payments
  8. E.R. Squibb & Sons, L.L.C. $126 7 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $126 7 payments
  10. Boston Scientific Corporation $116 5 payments
  11. Other $1,016 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,693 185 payments
  2. Debt forgiveness $67 2 payments
Products named General payments · program years 2019–2025
  1. Repatha Cardiology $504 26 payments
  2. VERQUVO $372 18 payments
  3. ENTRESTO $356 16 payments
  4. XARELTO $259 12 payments
  5. REPATHA Cardiovascular $203 11 payments
  6. JARDIANCE $169 7 payments
  7. VYNDAQEL $163 9 payments
  8. LEQVIO $135 7 payments
  9. ELIQUIS $131 8 payments
  10. LifeVest $126 7 payments
  11. Other $1,597 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,980

Median for Cardiology: 2,533

Drug cost

$540,872

Median for Cardiology: $485,213

Branded share of claims

23.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 245 $357,239
Xarelto Rivaroxaban Brand 54 $65,138
Entresto Sacubitril/Valsartan Brand 34 $45,624
Jardiance Empagliflozin Brand 15 $23,941
Brilinta Ticagrelor Brand 27 $20,163
Metoprolol Succinate Generic 259 $5,426
Rosuvastatin Calcium Generic 113 $2,750
Atorvastatin Calcium Generic 219 $2,509
Bumetanide Generic 49 $2,274
Ezetimibe Generic 25 $1,938

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$325,770

Of which drugs: $1,123

Medicare patients

1,287

Average age 78

Services billed

4,696

803 women, 484 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 38%
Ischemic heart disease 38%
Chronic kidney disease 38%
Atrial fibrillation 33%
Heart failure 28%
Depression 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 63 228 $1,123

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $267
$267 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $94
$94 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $68
$68 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $47
$47 — —
ELIQUIS
  • PFIZER INC. $34
$34 245 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record